Oral Mucositis (OM) is a severely debilitating condition that occurs secondary to radiotherapy and chemotherapy in cancer patients. It is important to maintain oral cleansing, reduce the risk of oral infections, and promote oral comfort. Oral care has been suggested to play a role in oral mucositis progression. The evidence on which agents can help was scarce so far. For the first time, we have two network meta-analyses (published in 2020) that have compared various oral care solutions and ranked them based on their beneficial role in preventing or reducing the severity of oral mucositis. Benzydamine mouthwash along with traditional curcumin & honey can prevent or reduce the severity of oral mucositis. This evidence can be utilized for a wider range of applications in dentistry – even in non-cancer patients.

1. Benzydamine Mouthwash, Curcumin And Honey
Prevent/ Reduce Oral Mucositis Severity
Oral Mucositis (OM) is a severely debilitating condition that occurs
secondary to radiotherapy and chemotherapy in cancer patients. It is
important to maintain oral cleansing, reduce the risk of oral infections, and
promote oral comfort. Oral care has been suggested to play a role in oral
mucositis progression. The evidence on which agents can help was scarce
so far. For the first time, we have two network meta-analyses (published in
2020) that have compared various oral care solutions and ranked them
based on their beneficial role in preventing or reducing the severity of oral
mucositis. Benzydamine mouthwash along with traditional curcumin & honey
can prevent or reduce the severity of oral mucositis. This evidence can be
utilized for a wider range of applications in dentistry – even in non-cancer
patients.
What is Mucositis?
Mucositis applies to the consequences secondary to cancer therapy –
chemotherapy and/ or radiation therapy; specifically, the mucosal damage
occurring in the oral cavity; pharyngeal, laryngeal, oesophagal regions; and
other gastrointestinal tract areas. It occurs in about 20% to 40% of patients
undergoing conventional chemotherapy and almost all patients who receive
head and neck radiation therapy (H&NRT).

2. What is OM?
OM is a severely disabling and commonly seen early chemotherapy and
radiotherapy effect. OM can trigger an inability to tolerate food or fluids, which
leads to malnutrition, dehydration, and weight loss.
How do we classify OM based on severity?
Depending on the severity, OM is grouped as
1. Tolerable mucositis (grade 1 and 2)
2. Intolerable mucositis (grade 3 or higher).
What are the consequences of intolerable mucositis?
Intolerable OM (grade 3 or higher) deserves more attention as large painful
ulcers characterize it. Pain leads to reduced food intake or nutritional
deficiencies. Also, mucositis induced dysphagia further reduces patients’
nutritional intake, leading to malnutrition and secondary bacterial and fungal
infections. As a result, the condition worsens, resulting in systemic symptoms
such as fatigue, anorexia and depression.
Drugs in OM:
Various drugs have been used to prevent and treat OM, but none have
achieved a satisfactory level.
Oral care and mouthwashes to prevent/ reduce the severity of OM:
Recently, oral care has been suggested to play a role in OM progression.
Different oral care solutions, such as chlorhexidine, benzydamine, sucralfate,
povidone-iodine, and honey, have been found to prevent mucositis or reduce
its severity.
Mouthwashes can maintain a clean oral environment and reduce the number of
bacteria in the oral cavity, thus reducing the risk of infection due to mucosal
damage, preventing OM in cancer patients.
Mouthwashes are economical and easy to use and are readily accepted by
patients. Plenty of research has happened regarding the use of mouthwashes
to prevent OM. However, we have two problems. First, we have a wide variety
of mouthwashes. Second, most studies focus on comparing mouthwash and
placebo; thus, there is a lack of direct comparison between different
mouthwashes, which means that it is difficult to provide evidence to guide
clinical practice.

3. Evidence on oral care solutions:
Systematic reviews and meta-analyses till the year 2020 that examined the
effects of the various oral care solutions on OM could only give out limited
evidence because classical meta-analysis methods did not allow comparisons
of multiple products.
In 2020, Bayesian network meta-analysis, a method combining all available
direct and indirect evidence on the relative treatment effects, enabling a
unified analysis of all randomized controlled trials was carried out for the first
time.
Bayesian network analysis (2020):
The study used appropriate statistical methods to merge direct and indirect
comparisons and sort different mouthwashes quantitatively to obtain the
optimal protocol.
The advanced methodology provided the basis for selecting the right
mouthwash to prevent intolerable OM development. The four most likely
efficacious interventions are chamomile, honey, curcumin, and benzydamine
mouthwashes.
Conclusion: According to the analysis of rank probabilities, chamomile,
honey, curcumin, and benzydamine mouthwashes are the most beneficial in
preventing intolerable OM.
Commonly available mouthwash benzydamine hydrochloride is a nonsteroidal
drug with proven topical anti-inflammatory, analgesic, anaesthetic, and
antimicrobial activities. Benzydamine reduces radiation-induced toxicity by
suppressing selected pro-inflammatory cytokine production – one of the
significant OM mechanisms.
International guidelines and recommendations:
International guidelines in this regard were published in 2004 and then
updated in 2007 and 2014. The MASCC/ISOO clinical practise guidelines
(2014) recommend that benzydamine mouthwash be used to prevent OM in
patients with cancer (level I evidence) – this is in agreement with the latest
Bayesian network analysis (2020).
What is a ‘level I’ evidence?
Level I consists of evidence that has more than one randomized controlled
trials without any significant flaws.

4. Relevance to dental practice:
Benzydamine mouthwash has been in use for many years. Now, the literature
gives the much needed evidence-based confidence to the practitioners that if
benzydamine can reduce the severity and provide comfort in a condition as
severe as OM from cancer therapy, it can undoubtedly provide comfort in less
severe, day-to-day cases of mucosal erythema, burning and discomfort while
having food and fluids.
1. Any mucosal burning, pain or discomfort.
2. Trauma from orthodontic braces, oral surgery appliances where the
patient can not apply the local anaesthetic gel, topical steroid gel etc.
3. Ulcers over a wide area inside the mouth
4. Hot food/ beverage or allergic reaction to a food ingredient leading to
burning and discomfort that urgently needs relief.
Curcumin and Honey:
Another network meta-analysis, also published in 2020, ranked curcumin,
honey and benzydamine as the top three interventions to prevent OM or
reduce its severity. Hence, in both the latest meta-analyses, two things have
become clear. A commonly available mouthwash like benzydamine and
homecare with curcumin and honey can benefit OM patients greatly in
improving their quality of life.
References:
1. Yu YY, Deng JL, Jin XR, Zhang ZZ, Zhang XH, Zhou X. Effects of nine
oral care solutions on the prevention of oral mucositis: A network meta-
analysis of randomized controlled trials. Medicine. 2020;99:16(e19661).
2. Zhang, X., Sun, D., Qin, N., Liu, M., Zhang, J., & Li, X. (2020).
Comparative prevention potential of 10 mouthwashes on intolerable oral
mucositis in cancer patients: A Bayesian network analysis. Oral
Oncology, 107, 104751. doi:10.1016/j.oraloncology.2020.104751
3. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire
DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE,
Sonis ST, Elad S; Mucositis Guidelines Leadership Group of the
Multinational Association of Supportive Care in Cancer and International
Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice
guidelines for the management of mucositis secondary to cancer
therapy. Cancer. 2014 May 15;120(10):1453-61. doi:
10.1002/cncr.28592. Epub 2014 Feb 25. Erratum in: Cancer. 2015 Apr
15;121(8):1339. PMID: 24615748; PMCID: PMC4164022.

5. Read more like this here at:
https://www.icpahealth.com/blog/
Like & Follow us on:
Facebook: https://www.facebook.com/icpahealthproducts
Twitter: https://twitter.com/icpahealth
Instagram: https://www.linkedin.com/company/icpa-health-private-
limited/?trk=nav_account_sub_nav_company_admin
YouTube: https://www.youtube.com/channel/UC6oLmUvJvOOklZzQmPqBHKw
Instagram: https://www.instagram.com/icpahealthproducts/